MedTrace Logo

Checkpoint Blockade in COVID-19 Pandemic

NCT04335305 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-06-21

No results posted yet for this study

Summary

This is a prospective, multicenter, randomized, controlled, open-label, phase 2 clinical trial

Conditions

Interventions

DRUG

Tocilizumab

IV infusion over 60 minutes; 8 mg/kg (up to a maximum of 800 mg per dose); single dose

BIOLOGICAL

Pembrolizumab (MK-3475)

IV infusion over 30 minutes, 200 mg; single dose

Sponsors & Collaborators

  • MedSIR

    lead OTHER

Principal Investigators

  • Javier Cortés · IOB Institute of Oncology, Vall d´Hebron Institute of Oncology (VHIO)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-09
Primary Completion
2021-03-08
Completion
2021-06-21

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04335305 on ClinicalTrials.gov